NASDAQ:FPRXFive Prime Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Five Prime Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.70 +0.25 (+10.20 %) (As of 04/10/2020 08:00 AM ET) Add Compare Share Today's Range$2.54Now: $2.70▼$2.7550-Day Range$1.86MA: $3.17▼$5.3652-Week Range$1.75Now: $2.70▼$13.36Volume368,000 shsAverage Volume302,917 shsMarket Capitalization$98.25 millionP/E RatioN/ADividend YieldN/ABeta2.62 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; a collaboration agreement with Roche; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingFive Prime Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.25, Five Prime Therapeutics has a potential upside of 353.7% from its current price of $2.70.Amount of Analyst CoverageFive Prime Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesFive Prime Therapeutics has received 290 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFive Prime Therapeutics has received 236 “underperform” votes. (Add your “underperform” vote.)Community SentimentFive Prime Therapeutics has received 55.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote “Outperform” if you believe FPRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFive Prime Therapeutics does not currently pay a dividend.Dividend GrowthFive Prime Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Five Prime Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Five Prime Therapeutics is held by insiders.Percentage Held by Institutions72.10% of the stock of Five Prime Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Five Prime Therapeutics are expected to decrease by -17.19% in the coming year, from ($2.56) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Five Prime Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Five Prime Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFive Prime Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FPRX Previous Symbol CUSIPN/A CIK1175505 Webhttp://www.fiveprime.com/ Phone415-365-5600Debt Debt-to-Equity Ratio0.30 Current Ratio7.24 Quick Ratio7.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.87 million Price / Sales6.61 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.65Profitability EPS (Most Recent Fiscal Year)($3.92) Net Income$-137,200,000.00 Net Margins-922.43% Return on Equity-71.29% Return on Assets-50.29%Miscellaneous Employees209 Outstanding Shares36,390,000Market Cap$98.25 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive FPRX News and Ratings via Email Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:FPRX Rates by TradingView Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions How has Five Prime Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Five Prime Therapeutics' stock was trading at $2.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FPRX shares have decreased by 7.8% and is now trading at $2.70. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Five Prime Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Five Prime Therapeutics. When is Five Prime Therapeutics' next earnings date? Five Prime Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Five Prime Therapeutics. How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics Inc (NASDAQ:FPRX) issued its quarterly earnings data on Thursday, February, 27th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. The biotechnology company earned $3.21 million during the quarter, compared to analyst estimates of $4.05 million. Five Prime Therapeutics had a negative net margin of 922.43% and a negative return on equity of 71.29%. View Five Prime Therapeutics' earnings history. What price target have analysts set for FPRX? 6 Wall Street analysts have issued 12 month price targets for Five Prime Therapeutics' shares. Their forecasts range from $5.00 to $24.00. On average, they expect Five Prime Therapeutics' stock price to reach $12.25 in the next twelve months. This suggests a possible upside of 353.7% from the stock's current price. View analysts' price targets for Five Prime Therapeutics. Has Five Prime Therapeutics been receiving favorable news coverage? Headlines about FPRX stock have been trending very negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Five Prime Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutFive Prime Therapeutics. Are investors shorting Five Prime Therapeutics? Five Prime Therapeutics saw a decline in short interest in March. As of March 13th, there was short interest totaling 1,422,400 shares, a decline of 10.5% from the February 27th total of 1,590,000 shares. Based on an average daily volume of 373,700 shares, the short-interest ratio is currently 3.8 days. Currently, 4.0% of the shares of the stock are short sold. View Five Prime Therapeutics' Current Options Chain. Who are some of Five Prime Therapeutics' key competitors? Some companies that are related to Five Prime Therapeutics include Avadel Pharmaceuticals (AVDL), Trillium Therapeutics (TRIL), Kala Pharmaceuticals (KALA), Organogenesis (ORGO), Beyondspring (BYSI), NewLink Genetics (NLNK), Flexion Therapeutics (FLXN), Merus (MRUS), Crinetics Pharmaceuticals (CRNX), OrganiGram (OGI), Satsuma Pharmaceuticals (STSA), Syros Pharmaceuticals (SYRS), DURECT (DRRX), Puma Biotechnology (PBYI) and Axovant Sciences (AXON). What other stocks do shareholders of Five Prime Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), Novavax (NVAX), Clovis Oncology (CLVS), Opko Health (OPK), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), TG Therapeutics (TGTX), Amarin (AMRN) and Anavex Life Sciences (AVXL). Who are Five Prime Therapeutics' key executives? Five Prime Therapeutics' management team includes the following people: Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)Dr. Peder K. Jensen, Advisor & Director (Age 64)Mr. David V. Smith, Exec. VP & CFO What is Five Prime Therapeutics' stock symbol? Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX." How do I buy shares of Five Prime Therapeutics? Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Five Prime Therapeutics' stock price today? One share of FPRX stock can currently be purchased for approximately $2.70. How big of a company is Five Prime Therapeutics? Five Prime Therapeutics has a market capitalization of $98.25 million and generates $14.87 million in revenue each year. The biotechnology company earns $-137,200,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe. View additional information about Five Prime Therapeutics. What is Five Prime Therapeutics' official website? The official website for Five Prime Therapeutics is http://www.fiveprime.com/. How can I contact Five Prime Therapeutics? Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: What is the formula for calculating total return?
